ArticleFrontiers in immunology2026

Intratumoral heterogeneity as a potential biomarker for immunotherapy response and postoperative recurrence in NSCLC.

Yuhang Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.